Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process

Current Protein and Peptide Science

Volumn 10, Issue 5, 2009, Pages 509-528

  Groenning, M ^a   Frokjaer, S ^a   Vestergaard, B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amyloid; Fibrillation; Insulin; Mechanism; Monomeric intermediate; Nucleus; Oligomer; Structure

Indexed keywords

CONGO RED; INSULIN; INSULIN FIBRIL; THIOFLAVINE; UNCLASSIFIED DRUG;

BETA SHEET; BIREFRINGENCE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DIFFRACTION; ENVIRONMENTAL FACTOR; FLUORESCENCE ANALYSIS; HORMONE DETERMINATION; HORMONE STRUCTURE; HUMAN; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN FIBRILLATION; INSULIN SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN POLYMERIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; THERMODYNAMICS; THREE DIMENSIONAL IMAGING; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; AMYLOID; ANIMALS; BIOCHEMISTRY; CELL NUCLEUS; CONGO RED; HUMANS; INSULIN; KINETICS; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN CONFORMATION; THIAZOLES;

EID: 70349505749     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309789352038     Document Type: Review

References (196)

1. Shepherd, P.R.; Kahn, B.B. Glucose transporters and insulin action: Implications for insulin resistance and diabetes mellitus. N. Engl. J. Med., 1999, 341 (4), 248-257.
2. Taylor, R. Insulin action 1991. Clin. Endocrinol., 1991, 34, 159-171.
3. Zierath, J.R.; Krook, A.; Wallberg-Henriksson, H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia, 2000, 43, 821-835.
4. Nystrom, F.H.; Quon, M.J. Insulin signalling: metabolic pathways and mechanisms for specificity. Cell Signal., 1999, 11 (8), 563-574.
5. Ottensmeyer, F.P.; Beniac, D.R.; Luo, R.Z.; Yip, C.C. Mechanism of transmembrane signaling: insulin binding and the insulin receptor. Biochemistry, 2000, 39 (40), 12103-12112.
6. Banting, F.G.; Best, C.H. Pancreatic extracts. J. Lab. Clin. Med. 1922, 7, 464-472.
7. Hermeling, S.; Crommelin, D.; Schellekens, H.; Jiskoot, W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res., 2004, 21 (6), 897-903.
8. Brange, J.; Skelbaek-Pedersen, B.; Langkjaer, L.; Damgaard, U.; Ege, H.; Havelund, S.; Heding, L.G.; Jørgensen, K.H.; Lykkeberg, J.; Markussen, J.; Pingel, M.; Rasmussen, E. Galenics of insulin. The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations, Springer-Verlag: Berlin, 1987.
9. Johnson, I.S. Human insulin from recombinant DNA technology. Science, 1983, 219 (4585), 632-637.
10. Walsh, G. Pharmaceutical biotechnology products approved within the European Union. Eur. J. Pharm. Biopharm., 2003, 55 (1), 3-10.
11. Redwan, E.-R.M. Cumulative updating of approved biopharmaceuticals. Hum. Antibodies, 2007, 16 (3-4), 137-158.
12. van de Weert, M.; Jorgensen, L.; Moeller, E.H.; Frokjaer, S. Factors of importance for a successful delivery system for proteins. Expert Opin. Drug Deliv., 2005, 2 (6), 1029-1037.
13. Nielsen, L.; Frokjaer, S.; Carpenter, J.F.; Brange, J. Studies of the structure of insulin fibrils by fourier transform infrared (FTIR) spectroscopy and electron microscopy. J. Pharm. Sci., 2001, 90 (1), 29-37.
14. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm., 2005, 289, 1-30.
15. Nielsen, L.; Khurana, R.; Coats, A.; Frokjaer, S.; Brange, J.; Vyas, S.; Uversky, V.N.; Fink, A.L. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry, 2001, 40 (20), 6036-6046.
16. Sluzky, V.; Tamada, J.A.; Klibanov, A.M.; Langer, R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. USA, 1991, 88 (21), 9377-9381.
17. Brange, J.; Andersen, L.; Laursen, E.D.; Meyn, G.; Rasmussen, E. Toward understanding insulin fibrillation. J. Pharm. Sci., 1997, 86 (5), 517-525.
18. Grillo, A.O.; Edwards, K.T.; Kashi, R.S.; Shipley, K.M.; Hu, L.; Besman, M.J.; Middaugh, C.R. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry, 2001, 40, 586-595.
19. Onoue, S.; Ohshima, K.; Debari, K.; Koh, K.; Shioda, S.; Iwasa, S.; Kashimoto, K.; Yajima, T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res., 2004, 21 (7), 1274-1283.
20. Storkel, S.; Schneider, H.M.; Muntefering, H.; Kashiwagi, S. Iatrogenic, insulin-dependent, local amyloidosis. Lab. Invest., 1983, 48 (1), 108-111.
21. Dische, F.E.; Wernstedt, C.; Westermark, G.T.; Westermark, P.; Pepys, M.B.; Rennie, J.A.; Gilbey, S.G.; Watkins, P.J. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia, 1988, 31 (3), 158-161.
22. Waugh, D.F. The linkage of corpuscular protein molecules. I. A fibrous modification of insulin. J. Am. Chem. Soc., 1944, 66, 663.
23. Waugh, D.F.A fibrous modification of insulin. I: the heat precipitate of insulin. J. Am. Chem. Soc., 1946, 68, 247-250.
24. Waugh, D.F. Reactions involved in insulin fibril formation. Fed. Proc., 1946, 5, 111.
25. Jimenez, J.L.; Nettleton, E.J.; Bouchard, M.; Robinson, C.V.; Dobson, C.M.; Saibil, H.R. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA, 2002, 99 (14), 9196-9201.
26. Groenning, M.; Norrman, M.; Flink, J.M.; van de Weert, M.; Bukrinsky, J.T.; Schluckebier, G.; Frokjaer, S. Binding mode of Thioflavin T in insulin amyloid fibrils. J. Struct. Biol., 2007, 159 (3), 483-497.
27. Burke, M.J.; Rougvie, M.A. Cross-β protein structures. I: insulin fibrils. Biochemistry, 1972, 11 (13), 2435-2439.
28. Sunde, M.; Serpell, L.C.; Bartlam, M.; Fraser, P.E.; Pepys, M.B.; Blake, C.C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol., 1997, 273 (3), 729-739.
29. Nielsen, L.; Frokjaer, S.; Brange, J.; Uversky, V.N.; Fink, A.L. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry, 2001, 40 (28), 8397-8409.
30. Khurana, R.; Uversky, V.N.; Nielsen, L.; Fink, A.L. Is Congo red an amyloid-specific dye? J. Biol. Chem., 2001, 276 (25), 22715-22721.
31. Westermark, P.; Benson, M.D.; Buxbaum, J.N.; Cohen, A.S.; Frangione, B.; Ikeda, S.; Masters, C.L.; Merlini, G.; Saraiva, M.J.; Sipe, J.D. A primer of amyloid nomenclature. Amyloid, 2007, 14(3), 179-183..
32. Hellman, U.; Wernstedt, C.; Westermark, P.; O'Brien, T.D.; Rathbun, W.B.; Johnson, K.H. Amino acid sequence from degu islet amyloid-derived insulin shows unique sequence characteristics. Biochem. Biophys. Res. Commun., 1990, 169 (2), 571-577.
33. Westermark, G.T. Endocrine Amyloid. In Amyloid Proteins; Sipe, J.D.; Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2005, pp. 723-755.
34. Dobson, C.M. Protein folding and misfolding. Nature, 2003, 426 (6968), 884-890.
35. Rose, G.D.; Geselowitz, A.R.; Lesser, G.J.; Lee, R.H.; Zehfus, M.H. Hydrophobicity of amino acid residues in globular proteins. Science, 1985, 229 (4716), 834-838.
36. Brange, J.; Owens, D.R.; Kang, S.; Vølund, A. Monomeric insulins and their experimental and clinical implications. Diabetes Care, 1990, 13 (9), 923-954.
37. Brange, J.; Langkjaer, L. Insulin structure and stability. In Stability and Characterization of Protein and Peptide Drugs; Wang, J.; Pearlman, R.; Eds.; Plenum Press: New York, 1993, pp. 315-350.
38. Dzwolak, W.; Jansen, R.; Smirnovas, V.; Loksztejn, A.; Porowski, S.; Winter, R. Template-controlled conformational patterns of insulin fibrillar self-assembly reflect history of solvation of the amyloid nuclei. Phys. Chem. Chem. Phys., 2005, 7, 1349-1351.
39. Grudzielanek, S.; Velkova, A.; Shukla, A.; Smirnovas, V.; Tatarek-Nossol, M.; Rehage, H.; Kapurniotu, A.; Winter, R. Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways. J. Mol. Biol., 2007, 370 (2), 372-384.
40. Grudzielanek, S.; Smirnovas, V.; Winter, R. Solvation-assisted pressure tuning of insulin fibrillation: from novel aggregation pathways to biotechnological applications. J. Mol. Biol., 2006, 356 (2), 497-509.
41. Brange, J.; Havelund, S.; Hansen, P.E.; Langkjaer, L.; Sørensen, E.; Hildebrandt, P. Formulation of physically stable neutral insulin solutions for continuous infusion by delivery systems. In Hormone Drugs; Gueriguian, J.L.; Bransome, E.D.; Outschoorn, A.S.; Eds.; US Pharmacopoeial Convention, Inc.: Rockville, MD, 1982, pp. 96-105.
42. Nilsson, M.R.; Dobson, C.M. Chemical modification of insulin in amyloid fibrils. Protein Sci., 2003, 12, 2637-2641.
43. Brange, J. Stability of insulin: studies on the physical and chemical stability of insulin in pharmaceutical formulation. Kluwer Academic Publishers: Dordrecht, The Netherlands, Doctoral dissertation, 1994.
44. Nettleton, E.J.; Tito, P.; Sunde, M.; Bouchard, M.; Dobson, C.M.; Robinson, C.V. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys. J., 2000, 79 (2), 1053-1065.
45. Pedersen, J.S.; Hansen, S.; Bauer, R. The aggregation behavior of zinc-free insulin studied by small-angle neutron scattering. Eur. Biophys. J., 1994, 22 (6), 379-389.
46. Baker, E.N.; Blundell, T.L.; Cutfield, J.F.; Cutfield, S.M.; Dodson, E.J.; Dodson, G.G.; Crowfoot Hodgkin, D.M.; Hubbard, R.E.; Isaacs, N.W.; Reynolds, C.D.; Sakabe, K.; Sakabe, N.; Vijayan, N.M. The structure of 2Zn pig insulin crystals at 1.5 Å resolution. Phil. Trans. R Soc. Lond. B., 1988, 319, 369-456.
47. Helmerhorst, E.; Stokes, G.B. The self-association of insulin: determinations based on a differential gel adsorption procedure. Arch. Biochem. Biophys., 1986, 245 (1), 238-247.
48. Uversky, V.N.; Garriques, L.N.; Millett, I.S.; Frokjaer, S.; Brange, J.; Doniach, S.; Fink, A.L. Prediction of the association state of insulin using spectral parameters. J. Pharm. Sci., 2002, 92 (4), 847-858.
49. Frank, B.H.; Pekar, A.H.; Veros, A.J. Insulin and proinsulin conformation in solution. Diabetes, 1972, 21, 486-491.
50. Jeffrey, P.D.; Coates, J.H. An equilibrium ultracentrifuge study of the effect of ionic strength on the self-association of bovine insulin. Biochemistry, 1966, 5 (12), 489-498.
51. Weiss, M.A.; Nguyen, D.T.; Khait, I.; Inouye, K.; Frank, B.H.; Beckage, M.; O'Shea, E.; Shoelson, S.E.; Karplus, M.; Neuringer, L.J. Two-dimensional NMR and photo-CIDNP studies of the insulin monomer: assignment of aromatic resonances with application to protein folding, structure and dynamics. Biochemistry, 1989, 28, 9855-9873.
52. Whittingham, J.L.; Scott, D.J.; Chance, K.; Wilson, A.; Finch, J.; Brange, J.; Dodson, G.G. Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. J. Mol. Biol., 2002, 318 (2), 479-490.
53. Brems, D.N.; Brown, P.L.; Heckenlaible, L.A.; Frank, B.H. Equilibrium denaturation of insulin and proinsulin. Biochemistry, 1990, 29, 9289-9293.
54. Hansen, J.F. The self-association of zinc-free human insulin and insulin analogue B13-glutamine. Biophys. Chem., 1991, 39, 107-110.
55. Brange, J.; Volund, A. Insulin analogs with improved pharmacokinetic profiles. Adv. Drug Deliv. Rev., 1999, 35 (2-3), 307-335.
56. Dunn, M.F. Zinc..ligand interactions modulate assembly and stability of the insulin hexamer - a review. Biometals, 2005, 18 (4), 295-303.
57. 3f human insulin: Temperature or pressure induced? Acta Crystallogr., 2001, D57, 1091-1100.
58. Whittingham, J.L.; Chaudhuri, S.; Dodson, E.J.; Moody, P.C.E.; Dodson, G.G. X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agents, thiocyanate, methylparaben and phenol. Biochemistry, 1995, 34, 15553-15563.
59. Derewenda, U.; Derewenda, Z.; Dodson, E.J.; Dodson, G.G.; Reynolds, C.D.; Smith, G.D.; Sparks, C.; Swenson, D. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature, 1989, 338, 594-596.
60. 6 insulin hexamer that binds phenol. Biopolymers, 1992, 32, 441-445.
61. 6 hexameric insulin complexed with m-cresol and resorcinol. Acta Crystallogr., 2000, D56, 1541-1548.
62. Huus, K.; Havelund, S.; Olsen, H.B.; Sigurskjold, B.W.; vandeWeert, M.; Frokjaer, S. Ligand binding and thermostability of different allosteric states of the insulin zinc-hexamer. Biochemistry, 2006, 45 (12), 4014-4024.
63. 6 human insulin at 1.0 Å resolution. Acta Crystallogr., 2003, D59, 474-482.
64. Blundell, T.; Dodson, G.G.; Hodgkin, D.; Mercola, D. Insulin: the structure in the crystal and its reflection in chemistry and biology. In Advances in Protein Chemistry, Anfinsen, C.B.; Edsall, J.T.; Richards, F.M.; Eds.; Academic Press: New York and London, 1972.
65. Huus, K.; Havelund, S.; Olsen, H.B.; vandeWeert, M.; Frokjaer, S. Thermal dissociation and unfolding of insulin. Biochemistry, 2005, 44 (33), 11171-11177.
66. Hua, Q.X.; Weiss, M.A. Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate. J. Biol. Chem., 2004, 279 (20), 21449-21460.
67. Ahmad, A.; Millett, I.S.; Doniach, S.; Uversky, V.N.; Fink, A.L. Partially folded intermediates in insulin fibrillation. Biochemistry, 2003, 42 (39), 11404-11416.
68. Rafikova, E.R.; Kurganov, B.I.; Arutyunyan, A.M.; Kust, S.V.; Drachev, V.A.; Dobrov, E.N. A mechanism of macroscopic (amorphous) aggregation of the tobacco mosaic virus coat protein. Int. J. Biochem. Cell Biol., 2003, 35 (10), 1452-1460.
69. Thomas, T.M.; Scopes, R.K. The effects of temperature on the kinetics and stability of mesophilic and thermophilic 3-phosphoglycerate kinases. Biochem. J., 1998, 330, 1087-1095.
70. Arora, A.; Ha, C.; Park, C.B. Insulin amyloid fibrillation at above 100°C: New insights into Protein Folding Under Extreme Temperatures. Protein Sci., 2004, 13 (9), 2429-2436.
71. Schlichtkrull, J. In Insulin Crystals: Chemical and Biological Studies on Insulin Crystals and Insulin Zinc Suspensions, Ejnar Munksgaard Publishers: Copenhagen, 1958.
72. Gursky, O.; Badger, J.; Li, Y.; Caspar, D.L.D. Conformational changes in cubic insulin crystals in the pH range 7-11. Biophys. J., 1992, 63, 1210-1220.
73. Balschmidt, P.; Hansen, F.B. Structure of porcine insulin cocrystallized with clupeine Z. Acta Crystallogr., 1991, B47, 975-986.
74. Ahmad, A.; Uversky, V.N.; Hong, D.; Fink, A.L. Early events in the fibrillation of monomeric insulin. J. Biol. Chem., 2005, 280 (52), 42669-42675.
75. Dathe, M.; Gast, K.; Zirwer, D.; Welfle, H.; Mehlis, B. Insulin aggregation in solution. Int. J. Pept. Protein Res., 1990, 36 (4), 344-349.
76. Ahmad, A.; Millett, I.S.; Doniach, S.; Uversky, V.N.; Fink, A.L. Stimulation of insulin fibrillation by urea-induced intermediates. J. Biol. Chem., 2004, 279 (15), 14999-15013.
77. Nayak, A.; Sorci, M.; Krueger, S.; Belfort, G.A universal pathway for amyloid nucleus and precursor formation for insulin. Proteins, 2008, 74(3), 556-565.
78. Uversky, V.N.; Fink, A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta, Proteins Proteomics, 2004, 1698 (2), 131-153.
79. Yao, Z.P.; Zeng, Z.H.; Li, H.M.; Zhang, Y.; Feng, Y.M.; Wang, D.C. Structure of an insulin dimer in an orthorhombic crystal: the structure analysis of a human insulin mutant (B9 Ser - Glu). Acta Crystallogr., 1999, D55, 1524-1532.
80. Sawaya, M.R.; Sambashivan, S.; Nelson, R.; Ivanova, M.I.; Sievers, S.A.; Apostol, M.I.; Thompson, M.J.; Balbirnie, M.; Wiltzius, J.J.; McFarlane, H.T.; Madsen, A.O.; Riekel, C.; Eisenberg, D. Atomic structures of amyloid cross-β. spines reveal varied steric zippers. Nature, 2007, 447, 453-457.
81. Olsen, H.B.; Ludvigsen, S.; Kaarsholm, N.C. Solution structure of an engineered insulin monomer at neutral pH. Biochemistry, 1996, 35 (27), 8836-8845.
82. Jorgensen, A.M.; Olsen, H.B.; Balschmidt, P.; Led, J.J. Solution structure of the superactive monomeric des-[Phe(B25)] human insulin mutant: elucidation of the structural basis for the monomerization of des-[Phe(B25)] insulin and the dimerization of native insulin. J. Mol. Biol., 1996, 257 (3), 684-699.
83. Bocian, W.; Sitkowski, J.; Bednarek, E.; Tarnowska, A.; Kawecki, R.; Kozerski, L. Structure of human insulin monomer in water/acetonitrile solution. J. Biomol. NMR, 2008, 40 (1), 55-64.
84. Dzwolak, W.; Grudzielanek, S.; Smirnovas, V.; Ravindra, R.; Nicolini, C.; Jansen, R.; Loksztejn, A.; Porowski, S.; Winter, R. Ethanol-perturbed amyloidogenic self-assembly of insulin: looking for origins of amyloid strains. Biochemistry, 2005, 44 (25), 8948-8958.
85. Dzwolak, W.; Ravindra, R.; Lendermann, J.; Winter, R. Aggregation of bovine insulin probed by DSC/PPC calorimetry and FTIR spectroscopy. Biochemistry, 2003, 42, 11347-11355.
86. Dzwolak, W.; Ravindra, R.; Winter, R. Hydration and structure - the two sides of the insulin aggregation process. Phys. Chem. Chem. Phys., 2004, 6, 1938-1943.
87. Mollmann, S.H.; Jorgensen, L.; Bukrinsky, J.T.; Elofsson, U.; Norde, W.; Frokjaer, S. Interfacial adsorption of insulin: Conformational changes and reversibility of adsorption. Eur. J. Pharm. Sci., 2006, 27 (2-3), 194-204.
88. Zoete, V.; Meuwly, M.; Karplus, M. A comparison of the dynamic behavior of monomeric and dimeric insulin shows structural re-arrangements in the active monomer. J. Mol. Biol., 2004, 342 (3), 913-929.
89. Wahlbom, M.; Wang, X.; Lindstrom, V.; Carlemalm, E.; Jaskolski, M.; Grubb, A. Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping. J. Biol. Chem., 2007, 282 (25), 18318-18326.
90. Guo, Z.; Eisenberg, D. Runaway domain swapping in amyloid-like fibrils of T7 endonuclease I. Proc. Natl. Acad. Sci. USA, 2006, 103 (21), 8042-8047.
91. Vestergaard, B.; Groenning, M.; Roessle, M.; Kastrup, J.S.; van de Weert, M.; Flink, J.M.; Frokjaer, S.; Gajhede, M.; Svergun, D.I. A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLoS Biol., 2007, 5 (5), e134.
92. Jansen, R.; Dzwolak, W.; Winter, R. Amyloidogenic self-assembly of insulin aggregates probed by high resolution atomic force microscopy. Biophys. J., 2005, 88, 1344-1353.
93. Khurana, R.; Ionescu-Zanetti, C.; Pope, M.; Li, J.; Nielson, L.; Ramirez-Alvarado, M.; Regan, L.; Fink, A.L.; Carter, S.A. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys. J., 2003, 85 (2), 1135-1144.
94. Podestà, A.; Tiana, G.; Milani, P.; Manno, M. Early events in insulin fibrillization studied by time-lapse atomic force microscopy. Biophys. J., 2006, 90, 589-597.
95. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C.M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 2002, 416, 507-511.
96. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T.; Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA, 2000, 97 (2), 571-576.
97. Chafekar, S.M.; Baas, F.; Scheper, W. Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta, 2008, 1782 (9), 523-531.
98. Chromy, B.A.; Nowak, R.J.; Lambert, M.P.; Viola, K.L.; Chang, L.; Velasco, P.T.; Jones, B.W.; Fernandez, S.J.; Lacor, P.N.; Horowitz, P.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Self-assembly of A..(1-42) into globular neurotoxins. Biochemistry, 2003, 42 (44), 12749-12760.
99. Losic, D.; Martin, L.L.; Mechler, A.; Aguilar, M.I.; Small, D.H. High resolution scanning tunnelling microscopy of the β-amyloid protein (Aβ1-40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly. J. Struct. Biol., 2006, 155 (1), 104-110.
100. Cohen, A.S.; Calkins, E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature, 1959, 183, 1202-1203.
101. Krebs, M.R.H.; Bromley, E.H.C.; Rogers, S.S.; Donald, A.M. The mechanism of amyloid spherulite formation by bovine insulin. Biophys. J., 2005, 88, 2013-2021.
102. Serpell, L.C.; Sunde, M.; Benson, M.D.; Tennent, G.A.; Pepys, M.B.; Fraser, P.E. The protofilament substructure of amyloid fibrils. J. Mol. Biol., 2000, 300 (5), 1033-1039.
103. Shirahama, T.; Cohen, A.S. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol., 1967, 33 (3), 679-708.
104. Bouchard, M.; Zurdo, J.; Nettleton, E.J.; Dobson, C.M.; Robinson, C.V. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci., 2000, 9 (10), 1960-1967.
105. Garriques, L.N.; Frokjaer, S.; Carpenter, J.F.; Brange, J. The effect of mutations on the structure of insulin fibrils studied by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. J. Pharm. Sci., 2002, 91 (12), 2473-2480.
106. Goldsbury, C.; Kistler, J.; Aebi, U.; Arvinte, T.; Cooper, G.J. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J. Mol. Biol., 1999, 285 (1), 33-39.
107. Harper, J.D.; Lieber, C.M.; Lansbury, P.T.; Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β protein. Chem. Biol., 1997, 4 (12), 951-959.
108. Jimenez, J.L.; Guijarro, J.I.; Orlova, E.; Zurdo, J.; Dobson, C.M.; Sunde, M.; Saibil, H.R. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J., 1999, 18 (4), 815-821.
109. Serpell, L.C.; Sunde, M.; Fraser, P.E.; Luther, P.K.; Morris, E.P.; Sangren, O.; Lundgren, E.; Blake, C.C.F. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J. Mol. Biol., 1995, 254 (2), 113-118.
110. Brange, J.; Dodson, G.G.; Edwards, D.J.; Holden, P.H.; Whittingham, J.L. A model of insulin fibrils derived from the X-ray crystal structure of a monomeric insulin (despentapeptide insulin). Proteins, 1997, 27 (4), 507-516.
111. Ionescu-Zanetti, C.; Khurana, R.; Gillespie, J.R.; Petrick, J.S.; Trabachino, L.C.; Minert, L.J.; Carter, S.A.; Fink, A.L. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc. Natl. Acad. Sci. USA, 1999, 96 (23), 13175-13179.
112. Krebs, M.R.H.; MacPhee, C.E.; Miller, A.F.; Dunlop, I.E.; Dobson, C.M.; Donald, A.M. The formation of spherulites by amyloid fibrils of bovine insulin. Proc. Natl. Acad. Sci. USA, 2004, 101 (40), 14420-14424.
113. Yagi, N.; Ohta, N.; Iida, T.; Inoue, K. A microbeam X-ray diffraction study of insulin spherulites. J. Mol. Biol. 2006, 362 (2), 327-333.
114. Jansen, R.; Grudzielanek, S.; Dzwolak, W.; Winter, R. High pressure promotes circularly shaped insulin amyloid. J. Mol. Biol., 2004, 338 (2), 203-206.
115. Serpell, L.C.; Blake, C.C.; Fraser, P.E. Molecular structure of a fibrillar Alzheimer's Aβ fragment. Biochemistry, 2000, 39 (43), 13269-13275.
116. Guo, Z.; Eisenberg, D. The structure of a fibril-forming sequence, NNQQNY, in the context of a globular fold. Protein Sci., 2008, 17 (9), 1617-1623.
117. Yu, N.T.; Jo, B.H.; Chang, R.C.C.; Huber, J.D. Single-crystal raman spectra of native insulin: structures of insulin fibrils, glucagon fibrils and intact calf lens. Arch. Biochem. Biophys., 1974, 160 (2), 614-622.
118. Ortiz, C.; Zhang, D.; Ribbe, A.E.; Xie, Y.; Ben-Amotz, D. Analysis of insulin amyloid fibrils by Raman spectroscopy. Biophys. Chem., 2007, 128 (2-3), 150-155.
119. Ivanova, M.I.; Sawaya, M.R.; Gingery, M.; Attinger, A.; Eisenberg, D. An amyloid-forming segment of β2-microglobulin suggests a molecular model for the fibril. Proc. Natl. Acad. Sci. USA, 2004, 101 (29), 10584-10589.
120. Qin, Z.; Hu, D.; Zhu, M.; Fink, A.L. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry, 2007, 46 (11), 3521-3531.
121. Huang, K.; Maiti, N.C.; Phillips, N.B.; Carey, P.R.; Weiss, M.A. Structure-specific effects of protein topology on cross-β assembly: studies of insulin fibrillation. Biochemistry, 2006, 45 (34), 10278-10293.
122. Hong, D.P.; Ahmad, A.; Fink, A.L. Fibrillation of human insulin A and B chains. Biochemistry, 2006, 45 (30), 9342-9353.
123. Caughey, B.; Lansbury, P.T. Protofibrils, pores, fibrils and neurogeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26 (1), 267-298.
124. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300 (5618), 486-489.
125. Konarkowska, B.; Aitken, J.F.; Kistler, J.; Zhang, S.; Cooper, G.J. The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells. FEBS J., 2006, 273 (15), 3614-3624.
126. Hoshi, M.; Sato, M.; Matsumoto, S.; Noguchi, A.; Yasutake, K.; Yoshida, N.; Sato, K. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl. Acad. Sci. USA, 2003, 100 (11), 6370-6375.
127. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95 (11), 6448-6453.
128. Nilsberth, C.; Westlind-Danielsson, A.; Eckman, C.B.; Condron, M.M.; Axelman, K.; Forsell, C.; Stenh, C.; Luthman, J.; Teplow, D.B.; Younkin, S.G.; Naslund, J.; Lannfelt, L. The 'arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci., 2001, 4 (9), 887-893.
129. Sousa, M.M.; Cardoso, I.; Fernandes, R.; Guimarães, A.; Saraiva, M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy. Am. J. Pathol., 2001, 159 (6), 1993-2000.
130. Stefani, M.; Dobson, C.M. Protein aggregation and aggregate toxicity: New insight into protein folding, misfolding diseases and biological evolution. J. Mol. Med., 2003, 81, 678-699.
131. Mauro, M.; Craparo, E.F.; Podesta, A.; Bulone, D.; Carrotta, R.; Martorana, V.; Tiana, G.; San Biagio, P.L. Kinetics of different processes in human insulin amyloid formation. J. Mol. Biol., 2007, 366 (1), 258-274.
132. Fodera, V.; Librizzi, F.; Groenning, M.; van de Weert, M.; Leone, M. Secondary nucleation and accessible surface in insulin amyloid fibril formation. J. Phys. Chem. B, 2008, 112 (12), 3853-3858.
133. Naiki, H.; Higuchi, K.; Hosokawa, M.; Takeda, T. Fluorometric determination of amyloid fibrils in vitro using the flourescent dye, Thioflavin T. Anal. Biochem., 1989, 177, 244-249.
134. LeVine III, H. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol., 1999, 309 (18), 274-284.
135. Groenning, M.; Olsen, L.; van de Weert, M.; Flink, J.M.; Frokjaer, S.; Jorgensen, F.S. Study on the binding of Thioflavin T to β-sheetrich and non-β-sheet cavities. J. Struct. Biol., 2007, 158, 358-369.
136. Krebs, M.R.H.; Bromley, E.H.C.; Donald, A.M. The binding of thioflavin-T to amyloid fibrils: Localisation and implications. J. Struct. Biol., 2005, 149 (1), 30-37.
137. Khurana, R.; Coleman, C.; Ionescu-Zanetti, C.; Carter, S.A.; Krishna, V.; Grover, R.K.; Roy, R.; Singh, S. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol., 2005, 151 (3), 229-238.
138. Friedhoff, P.; Schneider, A.; Mandelkow, E.-M.; Mandelkow, E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry, 1998, 37 (28), 10223-10230.
139. Voropai, E.S.; Samtsov, M.P.; Kaplevskii, K.N.; Maskevich, A.A.; Stepuro, V.I.; Povarova, O.I.; Kuznetsova, I.M.; Turoverov, K.K.; Fink, A.L.; Uversky, V.N. Spectral properties of thioflavin T and its complexes with amyloid fibrils. J. Appl. Spectrosc., 2003, 70 (6), 868-874.
140. Sabate, R.; Lascu, I.; Saupe, S.J. On the binding of Thioflavin-T to HET-s amyloid fibrils assembled at pH 2. J. Struct. Biol., 2008, 162 (3), 387-396.
141. LeVine III, H. Thioflavin T interaction with amyloid β-sheet structures. Int. J. Exp. Clin. Invest., 1995, 2, 1-6.
142. Dobson, C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci., 1999, 24 (9), 329-332.
143. Smirnovas, V.; Winter, R.; Funck, T.; Dzwolak, W. Protein amyloidogenesis in the context of volume fluctuations: a case study on insulin. Chem. Phys. Chem., 2006, 7, 1046-1049.
144. Waugh, D.F.; Wilhelmson, D.F.; Commerford, S.L.; Sackler, M.L. Studies of the nucleation and growth reactions of selected types of insulin fibrils. J. Am. Chem. Soc., 1953, 75, 2592-2600.
145. Grudzielanek, S.; Jansen, R.; Winter, R. Solvational tuning of the unfolding, aggregation and amyloidogenesis of insulin. J. Mol. Biol., 2005, 351 (4), 879-894.
146. Librizzi, F.; Fodera, V.; Vetri, V.; Lo, P.C.; Leone, M. Effects of confinement on insulin amyloid fibrils formation. Eur. Biophys. J., 2007, 36 (7), 711-715.
147. Waugh, D.F.; Smith, M.J.; Fearing, D.F. Regeneration of insulin fibrils with several reagents and the nature of the inter-insulin bond. Fed. Proc., 1948, 7 (1), 131.
148. Collins, S.R.; Douglass, A.; Vale, R.D.; Weissman, J.S. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol., 2004, 2 (10), 1582-1590.
149. Serio, T.R.; Cashikar, A.G.; Kowal, A.S.; Sawicki, G.J.; Moslehi, J.J.; Serpell, L.; Arnsdorf, M.F.; Lindquist, S.L. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science, 2000, 289, 1317-1321.
150. Sluzky, V.; Klibanov, A.M.; Langer, R. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol. Bioeng., 1992, 40, 895-903.
151. Garriques, L.N. Studies on insulin fibril formation. HCØ Tryk, Copenhagen, Denmark, PhD thesis, 2001.
152. Librizzi, F.; Rischel, C. The kinetic behavior of insulin fibrillation is determined by heterogeneous nucleation pathways. Protein Sci. 2005, 14, 3129-3134.
153. Oosawa, F.; Asakura, S. Thermodynamics of the Polymerization of Protein, Academic Press Inc.: London, 1975.
154. Jarrett, J.T.; Lansbury, P.T.; Jr. Amyloid fibril formation requires a chemically discriminating nucleation event: Studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry, 1992, 31 (49), 12345-12352.
155. Jarrett, J.T.; Lansbury, P.T.; Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 1993, 73 (6), 1055-1058.
156. Kundu, B.; Maiti, N.R.; Jones, E.M.; Surewicz, K.A.; Vanik, D.L.; Surewicz, W.K. Nucleation-dependent conformational conversion of the Y145Stop variant of human prion protein: structural clues for prion propagation. Proc. Natl. Acad. Sci. USA, 2003, 100 (21), 12069-12074.
157. Bhattacharyya, A.M.; Thakur, A.K.; Wetzel, R. Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc. Natl. Acad. Sci. USA, 2005, 102 (43), 15400-15405.
158. Naiki, H.; Nakakuki, K. First-order kinetic model of Alzheimer's βamyloid fibril extension in vitro. Lab. Invest., 1996, 74 (2), 374-383.
159. Harper, J.D.; Lansbury, P.T.; Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
160. Ferrone, F. Analysis of protein aggregation kinetics. Methods Enzymol., 1999, 309, 256-274.
161. Waugh, D.F. A mechanism for the formation of fibrils from protein molecules. J. Cell. Comp. Physiol., 1957, 49 (suppl. 1), 145-164.
162. Waugh, D.F. Protein-protein interactions. Adv. Protein Chem., 1954, 9, 325-437.
163. Doty, P.; Myers, G.E.II. Low molecular weight proteins. Thermodynamics of the association of insulin molecules. Discuss. Faraday Soc., 1953, 13, 51-58.
164. Naiki, H.; Gejyo, F. Kinetic analysis of amyloid fibril formation. Methods Enzymol., 1999, 20, 305-318.
165. Bitan, G.; Lomakin, A.; Teplow, D.B. Amyloid β-protein oligomerization: Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem., 2001, 276 (37), 35176-35184.
166. Hurshman, A.R.; White, J.T.; Powers, E.T.; Kelly, J.W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry, 2004, 43 (23), 7365-7381.
167. Powers, E.T.; Powers, D.L. The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration". Biophys. J., 2006, 91 (1), 122-132.
168. Ban, T.; Hamada, D.; Hasegawa, K.; Naiki, H.; Goto, Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem., 2003, 278 (19), 16462-16465.
169. Modler, A.J.; Fabian, H.; Sokolowski, F.; Lutsch, G.; Gast, K.; Damaschun, G. Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid, 2004, 11, 215-231.
170. Kodaka, M. Requirements for generating sigmoidal time-course aggregation in nucleation-dependent polymerization model. Biophys. Chem., 2004, 107, 243-253.
171. Ferrone, F.A.; Ivanova, M.; Jasuja, R. Heterogeneous nucleation and crowding in sickle hemoglobin: an analytic approach. Biophys. J., 2002, 82 (1), 399-406.
172. Ivanova, M.; Jasuja, R.; Kwong, S.; Briehl, R.W.; Ferrone, F.A. Nonideality and the nucleation of sickle hemoglobin. Biophys. J., 2000, 79 (2), 1016-1022.
173. Ferrone, F.A. Kinetics of sickle hemoglobin polymerization II: a double nucleation mechanism. J. Mol. Biol., 1985, 183, 611-631.
174. Firestone, M.P.; de Levie, R. On one-dimensional nucleation and growth of "living" polymers. I. Homogeneous nucleation. J. Theor. Biol., 1983, 104, 535-552.
175. Everett, D.H. Some thermodynamic aspects of aggregation phenomena with special reference to micellization. Colloids Surf., 1986, 21, 41-53.
176. Galina, H.; Lechowicz, J.B. Mean-field kinetic modeling of polymerization: The Smoluchowski coagulation equation. Adv. Polym. Sci., 1998, 137, 135-172.
177. Myers, D. Surfaces, Interfaces and colloids. Principles and applications, 2nd ed., Wiley-VCH: New York, 1999.
178. Smoluchowski, M.v. Versuch einer mathematischen theorie der koagulationskinetik kolloider lösungen. Z. Phys. Chem., 1918, 92, 129-168.
179. Modler, A.J.; Gast, K.; Lutsch, G.; Damaschun, G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J. Mol. Biol., 2003, 325 (1), 135-148.
180. Tomski, S.J.; Murphy, R.M. Kinetics of aggregation of synthetic β-amyloid peptide. Arch. Biochem. Biophys., 1992, 294 (2), 630-638.
181. Krapivsky, P.L.; Redner, S. Transitional aggregation kinetics in dry and damp environments. Phys. Rev. E, 1996, 54 (4), 3553-3561.
182. Flyvbjerg, H.; Jobs, E.; Leibler, S. Kinetics of self-assembling microtubules: An "inverse problem" in biochemistry. Proc. Natl. Acad. Sci. USA, 1996, 93 (12), 5975-5979.
183. Vajo, Z.; Fawcett, J.; Duckworth, W.C. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr. Rev. 2001, 22 (5), 706-717.
184. Rave, K.; Heinemann, L.; Puhl, L.; Gudat, U.; Woodworth, J.R.; Weyer, C.; Heise, T. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care, 1999, 22 (5), 865-866.
185. Olsen, H.B.; Kaarsholm, N.C. Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin. Biochemistry, 2000, 39 (39), 11893-11900.
186. Kurtzhals, P. Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. Int. J. Obes. Relat. Metab. Disord., 2004, 28 (Suppl 2), S23-S28.
187. Havelund, S.; Plum, A.; Ribel, U.; Jonassen, I.; Volund, A.; Markussen, J.; Kurtzhals, P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res., 2004, 21 (8), 1498-1504.
188. Berti, L.; Kellerer, M.; Bossenmaier, B.; Seffer, E.; Seipke, G.; Haring, H.U. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm. Metab. Res., 1998, 30 (3), 123-129.
189. Heinemann, L.; Linkeschova, R.; Rave, K.; Hompesch, B.; Sedlak, M.; Heise, T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 2000, 23 (5), 644-649.
190. Hallas-Møller, K.; Petersen, K.; Schlichtkrull, J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science, 1952, 116 (3015), 394-398.
191. Scholtz, H.E.; Pretorius, S.G.; Wessels, D.H.; Becker, R.H. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia, 2005, 48 (10), 1988-1995.
192. Wagner, A.; Diez, J.; Schulze-Briese, C.; Schluckebier, G. Crystal structure of Ultralente-A microcrystalline insulin suspension. Proteins, 2008, 74, 1018-1027
193. Stigsnaes, P.; Frokjaer, S.; Bjerregaard, S.; van de, W.M.; Kingshott, P.; Moeller, E.H. Characterisation and physical stability of PEGylated glucagon. Int. J. Pharm., 2007, 330 (1-2), 89-98.
194. Strack, T.R. Inhaled human insulin. Drugs Today (Barc.), 2006, 42 (4), 207-221.
195. Black, C.; Cummins, E.; Royle, P.; Philip, S.; Waugh, N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: A systematic review and economic evaluation. Health Technol. Assess., 2007, 11 (33), 1-126.
196. Cammarata, M.; Levantino, M.; Schotte, F.; Anfinrud, P.A.; Ewald, F.; Choi, J.; Cupane, A.; Wulff, M.; Ihee, H. Tracking the structural dynamics of proteins in solution using time-resolved wide-angle X-ray scattering. Nat. Methods, 2008, 5 (10), 881-886.